WEDGE(000534)2023-02-27 16:00Financial Performance - The company's operating revenue for 2022 was CNY 793,843,031.64, representing a 20.97% increase compared to CNY 656,255,549.80 in 2021[20]. - The net profit attributable to shareholders of the listed company was CNY 101,719,117.75, a 6.74% increase from CNY 95,292,383.72 in the previous year[20]. - The net profit after deducting non-recurring gains and losses was CNY 80,672,086.22, showing a significant increase of 73.55% from CNY 46,484,032.82 in 2021[20]. - The net cash flow from operating activities reached CNY 194,886,261.83, up 42.60% from CNY 136,667,738.73 in the previous year[20]. - The total assets at the end of 2022 were CNY 2,434,804,891.48, reflecting a 14.99% increase from CNY 2,117,454,697.21 at the end of 2021[20]. - The net assets attributable to shareholders of the listed company were CNY 1,192,252,473.62, an increase of 11.30% from CNY 1,071,171,820.88 in 2021[20]. - The basic earnings per share for 2022 were CNY 0.2033, a 5.56% increase from CNY 0.1926 in the previous year[20]. - The diluted earnings per share were CNY 0.2006, up 5.80% from CNY 0.1896 in 2021[20]. - The weighted average return on net assets was 8.87%, a decrease of 0.33 percentage points from 9.20% in the previous year[20]. Revenue Breakdown - Total revenue for the first quarter was ¥136,369,239.24, second quarter ¥238,262,847.19, third quarter ¥206,696,246.69, and fourth quarter ¥212,514,698.52[24]. - The manufacturing sector contributed CNY 180.32 million to total revenue, representing 22.71% of the total, with a significant year-on-year growth of 92.61%[48]. - The pharmaceutical manufacturing sector generated CNY 593.59 million, accounting for 74.77% of total revenue, with a growth of 7.84%[48]. - The southern region accounted for 76.06% of total revenue, with a year-on-year increase of 28.60%[48]. Product Development and R&D - The company completed the R&D of 28 new products, with 8 transitioning to mass production during the reporting period[45]. - The company has applied for a total of 30 invention patents and 25 utility model patents, with 33 patents granted as of December 31, 2022[45]. - The company has achieved an annual production capacity of 10,000 single crystal/directional turbine blade castings, successfully transitioning from research to mass production[43]. - The company has initiated multiple national and provincial-level research projects, including the development of a new generation of high-temperature alloy blades and advanced directional solidification technology[43]. - The company has developed the third-generation powder alloy WZ-A3, which is primarily used in advanced aviation engine turbine discs and other key hot-end components[43]. - The company aims to develop approximately 10 new probiotic strains annually through its probiotic strain library project, which is expected to enhance future product offerings[60]. Marketing and Sales - The company has a nationwide multi-channel marketing system, collaborating with major pharmaceutical groups and over 3,000 hospitals[36]. - The company has established a comprehensive marketing strategy combining brand, academia, and service, and has conducted nearly 2,000 activities under the "365 Public Welfare Plan" by the end of 2022[41]. Cash Flow and Investments - The company reported a net cash outflow from investment activities of ¥386,145,789.65 in 2022, a drastic decline of 406.67% from the previous year's outflow of ¥76,212,993.53[64]. - Total cash inflow from financing activities surged to ¥726,660,498.84 in 2022, marking a 232.81% increase from ¥218,338,581.35 in 2021[65]. - The net increase in cash and cash equivalents was -¥29,024,086.60 in 2022, an improvement of 57.77% from -¥68,734,324.44 in 2021[64]. Shareholder Matters - The company plans to distribute a cash dividend of CNY 0.5 per 10 shares (including tax) to all shareholders[5]. - The total distributable profit for the period is RMB 141,380,759.41, with the cash dividend representing 100% of the total profit distribution[130]. - The cash dividend policy complies with the company's articles of association and has been approved by the board, ensuring transparency and protection of minority shareholders' rights[130][134]. Governance and Compliance - The company actively maintains a governance structure that protects the interests of shareholders, particularly minority shareholders, through a balanced management mechanism[153]. - The company has established a comprehensive internal control system to ensure compliance and asset security, enhancing operational efficiency[144]. - The company reported that 100% of the total assets and operating income of the evaluated units were included in the internal control evaluation scope[146]. Future Outlook - The company anticipates that 2023 will be a year of economic recovery in China, with ongoing structural adjustments in the medical and pharmaceutical sectors[81]. - The high-temperature alloy industry in China is experiencing rapid expansion, driven by advancements in domestic aircraft engine development and increasing localization rates for large aircraft[82]. - In 2023, the company aims to implement its "14th Five-Year Plan" strategy despite a challenging external environment, with a focus on enhancing economic resilience and recovery[82].